BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immunovaccine Inc. to Present at Biotech Showcase(TM) 2011


1/5/2011 9:57:18 AM

HALIFAX, NOVA SCOTIA--(Marketwire - January 05, 2011) - Immunovaccine Inc. (TSX VENTURE: IMV) announced today that Dr. Randal Chase, President and CEO, will present at Biotech Showcase on Tuesday, January 11, 2011 in San Francisco, CA.

The presentation will include an update on the Phase I preliminary safety results of DPX-0907, the Company's first-in-man therapeutic cancer vaccine targeting patients with breast, ovarian and prostate cancer. Dr. Chase will also provide a corporate update on the development status of DPX-Survivac, a therapeutic cancer vaccine targeting ovarian cancer and an overview of recent partners who are applying Immunovaccine's DepoVax™ vaccine delivery platform to additional vaccines in development.

Biotech Showcase provides companies an opportunity to present to investors and biopharmaceutical executives during the course of the annual JP Morgan Healthcare conference, the industry's largest annual healthcare investor conference. www.biotechshowcase.com

About Immunovaccine

Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery platform and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Contacts:
Immunovaccine Inc.
Jennifer Ayotte
Director Communications
(902) 209-4704
jayotte@imvaccine.com
www.imvaccine.com

Tiberend Strategic Advisors, Inc.
Andrew Mielach
(212) 827-0020
amielach@tiberendstrategicadvisors.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES